A Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced From EU and US in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors JHL Biotech
- 04 Sep 2018 Planned End Date changed from 8 Sep 2018 to 31 Jan 2019.
- 04 Sep 2018 Planned primary completion date changed from 4 Aug 2018 to 15 Sep 2018.
- 16 Apr 2018 According to a JHL Biotech media release, the data from this and other trials will support the global registration and commercialization of JHL1149.